Our IP-protected profiling platform creates hundreds of patient-derived live 3D microtumors and uses AI/ML analytics to identify most effective treatments with clinical-grade accuracy, delivering actionable results in 7–10 days.
By enabling more informed treatment selection beyond histology and genomics, this approach is poised to significantly increase tumor response rates, overall survival, and quality of life for many cancer patients.